RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Canada Updates Clinical Trial Guidance

Canada Updates Clinical Trial Guidance

Posted 24 June 2013 | By Louise Zornoza

Health Canada has released revised clinical trials guidance for sponsors and trial applications explaining the application requirements for comparative bioavailability trials and filing requirements for the importation of clinical trial supplies.

It also includes clarifications to amendment and notification requirements, study termination and closure criteria, application and review processes, and adverse drug reaction reporting criteria as well as format requirements. The Guidance for Clinical Trial Applications (CTAs) is consistent with the new Common Technical Document (CTD) format.

The revised guidance applies to all sponsors (such as industry, academic, contract research organization) conducting the following clinical trials:

  • Trials of a product that is not authorized for sale in Canada including Phases I through III of drug development and comparative bioavailability studies.
  • Trials for marketed drugs where the proposed use of the drug is outside the parameters of the Notice of Compliance (NOC) or Drug Identification Number (DIN) application.
  • Clinical Trial Application Amendments (CTA-A) [C.05.008] and Notifications (CTA-N) [C.05.007].

The guidance does not apply to Phase IV clinical trials or clinical trials involving medical devices or natural health products except where indicated. 


Health Canada: Revised Clinical Trials Guidance

Read all Breaking News from RegLink

 

© 2022 Regulatory Affairs Professionals Society.